Ahmed Azaz, Köhler Sophia, Klotz Rosa, Giese Nathalia, Hackert Thilo, Springfeld Christoph, Jäger Dirk, Halama Niels
Medical Oncology and Internal Medicine VI, National Center for Tumor Diseases (NCT), University Hospital Heidelberg, University Heidelberg, 69120 Heidelberg, Germany.
Translational Immunotherapy, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Cancers (Basel). 2023 Mar 17;15(6):1815. doi: 10.3390/cancers15061815.
Mounting evidence suggests that sex plays a critical role in various aspects of cancer such as immune responses. However, a male bias exists in human and non-human studies including immunotherapy trials. The role of sex on immune responses in pancreatic ductal adenocarcinoma (PDA) is unclear.
Here, tumor tissues (tumor and stroma separately) and corresponding blood samples from patients with PDA ( = 52) were systematically analyzed by immunohistochemistry and multiplex cytokine measurements and compared by sex.
Females showed a stronger systemic immune response with higher levels of CXCL9, IL1B, IL6, IL10 and IL13. Additionally, more peripheral white blood cells were detected in females. In the microenvironment, males showed higher tumoral levels of CXCL12. No differences were detected in the stroma. Females showed a tendency towards an anti-tumoral immune cell profile. CXCL12 blockade indicated a differential microenvironmental effect by sex in an independent immunotherapy trial cohort of patients with PDA (one female, five males). The overall survival did not differ by sex in our cohort.
Systemic and local immune responses differ between sexes in PDA. Accordingly, sex-dependent differences need to be considered in human studies and for specific immunological interventions before clinical translation.
越来越多的证据表明,性别在癌症的各个方面(如免疫反应)中起着关键作用。然而,在包括免疫治疗试验在内的人类和非人类研究中存在男性偏见。性别在胰腺导管腺癌(PDA)免疫反应中的作用尚不清楚。
在这里,通过免疫组织化学和多重细胞因子测量对52例PDA患者的肿瘤组织(分别为肿瘤和基质)及相应血液样本进行系统分析,并按性别进行比较。
女性表现出更强的全身免疫反应,CXCL9、IL1B、IL6、IL10和IL13水平更高。此外,在女性中检测到更多外周血白细胞。在微环境中,男性肿瘤组织中CXCL12水平较高。在基质中未检测到差异。女性表现出抗肿瘤免疫细胞谱的倾向。在一个独立的PDA患者免疫治疗试验队列(1名女性,5名男性)中,CXCL12阻断显示出性别对微环境的不同影响。在我们的队列中,总体生存率在性别上没有差异。
PDA中两性的全身和局部免疫反应存在差异。因此,在临床转化之前,人类研究和特定免疫干预中需要考虑性别依赖性差异。